Kymriah, Blincyto and Besponsa to drive acute lymphocytic leukemia market growth

30 November 2020

The acute lymphocytic leukemia (ALL) market has enjoyed explosive growth since 2015 and is expected to increase further, albeit at a slower pace, from $1.46 billion in 2019 to $2.26 billion in 2029, across the eight major markets.

This growth will take place at a moderate compound annual growth rate (CAGR) of 4.4%, according to GlobalData, in its latest report, ‘Acute Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2029.

The report predicts that the increase will come about through already successful agents, namely Novartis’ (NOVN: VX) Kymriah (tisagenlecleucel), Amgen’s (Nasdaq: AMGN) Blincyto (blinatumomab) and Pfizer’s (NYSE: PFE) Besponsa (inotuzumab ozogamicin), in more patient populations, and by the regulatory approval of late-stage pipeline agents.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK